Androgenetic alopecia (AGA) is a nonscarring alopecia due to hormonal and genetic influences and is characterized by the progressive miniaturization of hair follicles, with the transformation of terminal hair into vellus hair. Female pattern hair loss is a term that is used latently to describe AGA in females. 1 The frequency and severity of AGA increase with the increasing age of the patients. 2 The major pathogenic cause of AGA is a dihydrotestosterone (DHT) imbalance, which might interfere with the progressive miniaturization of scalp hair. Most of the research in this field is aimed at solving this problem by medical therapy that has been used effectively for androgenetic alopecia (AGA). FDA approved two therapies for AGA: topical minoxidil and oral finasteride. 3 Many authors investigated adding some procedures as co-adjuvant therapies for AGA as mesotherapy, platelet-rich plasma (PRP), stem cell therapies, that is, adipose-derived mesenchymal stem cells (AD-MSCs), and human follicle stem cells (HFSCs). 4,5 Platelet-rich plasma is an emerging treatment for AGA. It is an autologous solution drawn from one's blood that has been centrifuged and filtered to contain a high concentration of platelets and their bioactive growth factors. 4,6 The use of PRP is promising adjuvant therapy for AGA. Safety issues, downtime, and side effects seem to be minimal. PRP

An in vitro study showed that OBO (natural product) exerts fungistatic and fungicidal activity against a variety of pathogenic dermatophyte species. It is a promising, cheap, and available topical antifungal therapeutic agent.

No abstract

No abstract

No abstract